Lexogen is committed to continue its operations and is taking sensible precautions to minimize any potential impact of COVID-19 to our employees and our customers.

As product security and product quality are our biggest concerns, we are further tightening our already stringent working conditions, that our personnel normally follow in an RNA products focused company.

In the given situation, we are particularly engaged to maintain supply continuity, by implementing specific measures to minimize any disruption risks:

  • Increased levels of hygiene
  • Global required work from home policy for those whose work is not on site critical.
  • Reduced travel
  • Increased stock of products at all our warehouses

Effective immediately we are suspending production of trial kits, to focus our efforts on supplying the increased demand on our full products. 

As the situation might change any moment, we want to be able to supply our products to meet any higher demands from our customers all over the world.

Being an RNA-focused company, we know that our products are central to understanding the disease and support researchers who are fighting against it.

With my best regards,

Dr. Paolo Marcandalli
Sr. Manager Global Distributor Sales